120 days ago
90 days ago
30 days ago
7 days ago
Clinical trial, phase 1
Clinical trial, phase 2
Clinical trial, phase 3
Clinical trial, phase 4
Consensus development conference
Consensus development conference, NIH
Controlled clinical trial
Corrected republished article
Randomized controlled trial
All infant: 0-23 mos
All child: 0-18 yrs
All adult: 19+ yrs
Newborn: birth-1 mo
Preschooler: 2-5 yrs
Adolescent: 13-18 yrs
Young adult: 19-24 yrs
Middle-aged: 45-64 yrs
Aged: 65+ yrs
Elderly: 80+ yrs
PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation.
J Autoimmun (2011)
36(3-4):278-87 PMID 21396797
The Class IA phosphoinositide 3-kinase delta (PI3Kδ) has been implicated in multiple signaling pathways involved in leukocyte activation and hence is an attractive target in many human autoimmune diseases, including multiple sclerosis (MS). Here, using mice expressing a catalytically inactive form of the PI3Kδ subunit p110δ, we show that signaling through PI3Kδ is required for full and sustained pathology of experimental autoimmune encephalomyelitis (EAE), a Th17-driven model of MS. In p110δ-inactivated mice, T cell activation and function during EAE was markedly reduced and fewer T cells were observed in the central nervous system (CNS). The decrease in T cell activation is unlikely to be due to defects in dendritic cell (DC) function, as p110δ-inactivated DCs migrate and present antigen normally. However, significant increases in the proportion of T cells undergoing apoptosis at early stages of EAE were evident in the absence of PI3Kδ activity. Furthermore, a profound defect in Th17 cellular responses during EAE was apparent in the absence of PI3Kδ activity while Th1 responses were less affected. A highly selective PI3Kδ inhibitor, IC87114, also had greater inhibitory effects on Th17 cell generation in vitro than it did on Th1 cell generation. Thus, PI3Kδ plays an important role in Th17 responses in EAE, suggesting that small molecule inhibitors of PI3Kδ may be useful therapeutics for treatment of MS and other autoimmune diseases.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Version: za2963e q8zad q8zbe q8zca q8zd3 q8ze0 q8zf4 q8zgb
Similar articles you may find interesting…
TIE-2 and VEGFR kinase activities drive TIE-2-expressing monocytes immunosuppressive function in human breast tumors.
Clin Cancer Res (2013)
these results suggest that TEM are plastic cells that can be reverted from suppressive, pro-angiogenic cells, into cells that are able to mediate an anti-tumoral immune response....
Mucopolysaccharide diseases: A complex interplay between neuroinflammation, microglial activation and adaptive immunity.
J Inherit Metab Dis (2013)
I (MPS I), MPS IIIA, MPS IIIB and MPS VII are deficient in the enzymes α-L-Iduronidase, Heparan-N-Sulphatase, N-Acetylglucosaminidase and Beta-Glucuronidase, respectively. Enzyme deficiency leads to the progressive multi-systemic build-up of heparan sulphate (HS) and dermatan sulphate (DS) within c...
Impact of hormone replacement therapy use on mammographic screening outcomes.
Cancer Causes Control (2013)
Increased risks of recall, biopsy rates, screen-detected, and interval cancers among HRT users have important implications for population-based breast cancer screening programs. Our findings support the concept that HRT use may increase the growth of preexisting cancers. Lack of effect on DCIS could...
Place any articles on Pubget into your Bookmark folder to read later, download citations, or send to a colleague. Create an account or sign in to create your bookmarks.
Pubget Updates sends you emails when Pubget finds new papers that match your search. Use Pubget Updates to get the latest articles for your specialty, written by a colleague, or published by your favorite journals.